Comparative Pharmacology
Head-to-head clinical analysis: POSACONAZOLE versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSACONAZOLE versus POSFREA.
POSACONAZOLE vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
300 mg orally twice daily on day 1, then 300 mg once daily thereafter. Extended-release tablets: 300 mg orally twice daily on day 1, then 300 mg once daily. Intravenous: 300 mg IV twice daily on day 1, then 300 mg once daily.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Terminal elimination half-life: 35 hours (range 25–50 hours), allowing once-daily dosing after steady state; prolonged in hepatic impairment.
Clinical Note
moderatePosaconazole + Tranilast
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast."
Clinical Note
moderatePosaconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic acid."
Clinical Note
moderatePosaconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide."
Clinical Note
moderate12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Fecal (77% as unchanged drug) and renal (14% as glucuronide conjugates); <1% excreted unchanged in urine.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category C
Category C
Azole Antifungal
Azole Antifungal
Posaconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronic acid."